<DOC>
	<DOCNO>NCT02043288</DOCNO>
	<brief_summary>This clinical trial design evaluate impact addition NC-6004 gemcitabine treatment patient locally advance metastatic pancreatic cancer Asian countires .</brief_summary>
	<brief_title>Combination Therapy With NC-6004 Gemcitabine Versus Gemcitabine Alone Pancreatic Cancer</brief_title>
	<detailed_description>Pancreatic cancer one deadly cancer predominately late diagnosis . Gemcitabine ( GEM ) standard treatment advance metastatic pancreatic cancer . According preclinical data early phase study , combine use gemcitabine cisplatin ( CDDP ) show synergistic efficacy pancreatic cancer . NC-6004 , novel micellar cisplatin formulation , retain activity avoids renal toxicity neurotoxicity cause high peak Cmax concentration cisplatin . This trial design evaluate impact addition NC-6004 gemcitabine treatment patient locally advance metastatic pancreatic cancer . The main hypothesis study NC-6004 plus gemcitabine combination superior gemcitabine alone term overall survival locally advance metastatic pancreatic cancer patient</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Male female age 20 80 year ( inclusive ) 2 . Unresectable , histologically cytologically confirm , locally advanced metastatic pancreatic cancer ( adenocarcinoma , adenosquamous carcinoma poorly differentiate carcinoma ) 3 . Presence least one measurable tumor lesion ( long diameter ≥ 10 mm ) 4 . No prior systemic anticancer therapy radiotherapy advance pancreatic cancer 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 6 . Adequate organ function define : 3,000 cells/μL ≤ White blood cell count ( WBC ) ≤ 12,000 cells/μL Absolute neutrophil count ( ANC ) ≥ 1,500 cells/μL Platelets ≥ 100,000 cells/μL Hemoglobin ( Hb ) ≥ 9.0 g/dL Alanine amino transferase ( ALT ) aspartate amino transferase ( AST ) ≤ 2.5 time upper limit normal ( ULN ) patient demonstrable hepatic metastasis , ≤ 5 x ULN patient hepatic metastasis Serum bilirubin ≤ 1.5 x ULN patient demonstrable hepatic metastasis obstructive jaundice , ≤ 2.5 x ULN patient hepatic metastasis obstructive jaundice Serum creatinine ( SCr ) ≤ 1.5 mg/dL creatinine clearance ( CrCl ) ≥ 60 mL/min ( 24hour urine test CockcroftGault formula ) Corrected serum calcium ≤ ULN 7 . If fertile , willing use barrier contraception till 6 month end treatment 8 . Willing able comply study procedure provide write informed consent 1 . Pregnancy breastfeed 2 . Active concomitant malignancy history cancer except carcinoma situ cervical squamous cell carcinoma , stage I colon cancer malignance remain diseasefree 3 year curative intervention 3 . Metastasis central nervous system brain 4 . Evidence hearing impaired ≥ Grade 2 assess pure tone audiometry neurotoxicity ≥ Grade 2 5 . Pulmonary fibrosis interstitial pneumonia 6 . Marked pleural effusion ascites Grade 2 7 . Patient known HIV infection 8 . Patient active hepatitis B , hepatitis C ongoing severe infection 9 . Severe mental disorder 10 . As judged investigator , evidence significant laboratory finding severe/uncontrolled clinical disorder ( e.g . dementia , myocardial infarction within 6 month prior enrollment , New York Heart Association ( NYHA ) Class III IV heart failure , unstable angina , active cardiomyopathy , unstable arrhythmia , unstable uncompensated respiratory , cardiac , hepatic , renal and/or infectious disease ) 11 . Patient known hypersensitivity Pt compound 12 . Known severe drug hypersensitivity 13 . Treatment nonapproved investigational product within 30 day Day 1 study treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Platinum</keyword>
	<keyword>Micelle</keyword>
</DOC>